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ABSTRACT  
Helicobacter pylori is a virulent human pathogen infecting about 50% of the population worldwide. Being a leading cause of gastric ulcer, duodenal 
ulcer, gastritis, dyspepsia, gastric tumorigenesis etc., this organism has been the focus of concerted study to establish uncertainty of its genetics, 
immunopathogenesis and cell biology. Scientists have tried to effectively eradicate this pathogen from the gastrointestinal tract in various manners. 
Inquest of this venture, gastroretentive drug delivery systems including floating dosage forms have emerged as a boon and offer significantly 
improved therapeutic effects of different antimicrobial drugs. This article presents an evocative review of the structural features, epidemiological 
evidences and various pharmacotherapeutics vistas. In addition, various novel gastroretentive dosage forms developed so far to combat 
Helicobacter pylori infection are also discussed. Comprehensive literature review has been performed for this manuscript by utilizing relevant 
databases like PubMed, SCOPUS, Web of Science, Science Direct, Google Scholar etc., from 1997 up to the year 2020.  
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INTRODUCTION  
Helicobacter pylori (H. pylori) is a spiral-shaped, micro-aerophilic 
and gram-negative bacteria. Campylobacter pyloridis is the earlier 
name of this pathogen, however; a new class has been introduced 
and currently, H. pylori is included in the family Helicobacteraceae, 
helicobacter genus [1, 2]. Helicobacter pylori bacterium was initially 
identified in human populations in 1906 and successfully cultured in 
1982 by Marshall and Warren, who jointly received 2005 Nobel 
Prize for their research on Helicobacter pylori [3-7]. This pathogen 
exists in the gastric mucous overlying the epithelium of the stomach, 
in more than 50 percent population of the entire world [8-12]. 
Colonization of H. pylori in the gastric region causes chronic gastric 
inflammation in all infected persons, with the clinical indication in 
10-20 percent [1].  
Helicobacter pylori infection associated ailments 
Infection associated with H. pylori includes peptic ulcers (duodenal 
ulcers and gastric ulcers), severe, recurrent and atrophic gastritis, 
gastric B cell lymphoma, gastric adenocarcinoma, intestinal 
metaplasia, mucosa-associated lymphoid tissue (MALT)-associated 
lymphoma etc [1, 13-19]. Typhoid fever has also independently 
associated with H. pylori [20]. Earlier epidemiologic evidence 
indicates that H. pylori infection increases the risk of gastric cancer. 
It has also been investigated that bacterium Helicobacter pylori-
induced infection is carcinogenic to human population [19, 21-26]. 
DNA damage caused by this bacterium may lead to the cancer 
development in the stomach. Earlier studies revealed that genomic 
regions demonstrate more susceptibility to H. pylori induced DNA 
disruption and are substantially associated with chromosomal 
modifications in stomach cancer [27, 28]. Some virulence factors are 
also responsible for chromosomal changes. Two of the main 
significant virulence factors include cytotoxin-associated gene A 
(CagA) and vacuolating cytotoxin (VacA) [5, 29-32]. Multiple 
findings suggest that Helicobacter pylori infection is correlated with 
a substantially higher risk of stomach cancer and longer the time 
interval between detection of Helicobacter pylori and diagnosis of 
stomach cancer, greater the risk of developing carcinoma [33]. 
Flagella and spiral structure of H. pylori allows selective adherence 
to the epithelium through gastrointestinal mucus gel [11, 13, 34]. 
Drinking water can also be a risk factor for bacterial transmission 
[35]. Moreover, H. pylori have also been cultured through vomitus, 
diarrheal stool and saliva [36]. Ailments related to 
Helicobacter pylori infection is presented in fig. 1.  
 
 
Fig. 1: H. pylori associated various ailments 
 
Immunological defence mechanisms against bacterial 
proliferation  
Several factors produced by mucosa of the stomach inhibit 
bacterial proliferation. Antibacterial peptides are active against 
several specific types of bacteria, which include LL37 and β 
defensins 1 and 2. Lactoferrin also hampers bacterial development. 
Lactoferricin, a lactoferrin-derived peptide, also has antimicrobial 
qualities. Lysozyme can also be responsible for bacterial 
peptidoglycan degradation [37]. By diminishing inflammation 
grades and bacterial population, the antimicrobial peptide 
cathelicidin may serve as a natural antibiotic against H. pylori. 
Another proposed method of managing Helicobacter pylori infection 
is to use fatty acids, as numerous experiments have demonstrated 
their antibacterial activity [27]. The binding of H. pylori to 
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gastrointestinal epithelial cells leads to triggering activation of 
various signalling mechanisms, which enables the effective 
transmission of toxic substances or other contaminants into gastric 
epithelium cells [37]. Findings in various animal models suggest that 
H. pylori's attachment to gastric epithelial cells affects the growth of 
inflammation in gastric mucosa, production autoantibodies, parietal 
cell diminution etc [37]. Urease and flagella are two crucial virulence 
factors for colonization of Helicobacter pylori successfully into the 
stomach [38]. Urease enzyme produced by Helicobacter pylori is 
responsible for mononuclear phagocytes activation along with 
enhancement in production of inflammatory cytokine, which creates 
favourable environment for bacteria to colonize [39, 40]. Diagnosis 
of infection is usually performed by diagnostic tests such as stool 
antigen test, urea breath test, blood antibody test etc [41, 42]. These 
tests determine whether a bacterial infection may induce ulcer or 
inflammation of stomach lining and also establish the effectiveness 
of the treatment strategies [43].  
Treatment strategies 
Several years ago, dual therapies which combined a proton pump 
inhibitor with either clarithromycin or amoxicillin were common. A 
large number of triple or quadruple treatments have also been 
reported. Triple therapy to eradicate Helicobacter pylori infection 
includes a metronidazole (or tinidazole), proton pump inhibitor 
along with clarithromycin. Few probiotic strains may minimize the 
probability of adverse effects and thus enhance the eradication rate 
of Helicobacter pylori [15, 24, 44-48]. In between 10-20 percent of 
cases, the most utilized medication regimens may also struggle. 
Quadruple therapy based on bismuth remains the primary choice for 
second-line treatment if not used as first-line therapy [15, 43, 47, 49-
53]. Recently, many researchers have an ultimate aim for 
considering H. pylori genomics for the development of new 
therapies. One example of this includes developing targeted 
interventions that eliminate H. pylori without disrupting commensal 
human bacteria. For example, recent work has identified HtrA and 
BioV (a synthetic biotin enzyme) as specific to H. pylori. These have 
potential for allowing the treatment of H. pylori without affecting the 
host or the resident microbiota [54]. It was also found that eating 
broccoli sprouts daily for two month can reduces H. pylori infection 
into the stomach [55]. It was reported that a Korean vegetable 
Kimichi may also eradicate H. pylori [56].  
Sometimes, several therapies to eradicate H. pylori are difficult and 
complex. Increased and indiscriminate utilization of antibiotics has 
led to significant failures in treatment [43]. Owing to high antibiotics 
resistance and inadequate patient compliance, new medications with 
enhanced efficacy in addition to simpler regimens are desired for the 
eradication of Helicobacter pylori [53]. Therefore, to attain a high 
wipeout rate of H. pylori from the stomach, it's obligatory that delivery 
of antibiotic to the whole surface of the abdomen is achieved and 
consequently, drug should reach in the desired amount for adequate 
time to destroy the bacterium. Gastroretentive drug delivery system is 
employed as a promising technology to provide advantageous results 
in site-specificity of antibiotics delivery. Retention of the delivery 
system is also ensured at a particular part of the gastrointestinal tract, 
wherever it is needed for local delivery and action at specific site [39].  
Gastroretentive drug delivery systems 
The oral route is recognized as the most preferred route for drug 
delivery. This route has many inherent advantages like convenience, 
cost-effectiveness, non-invasiveness, safety and patient 
compliance [57-59]. However, bioavailability of medicaments 
delivered through this route can change considerably, particularly if 
pharmacotherapeutic substances are delivered utilizing 
conventional types. Such constraints are usually due to inter-and 
intra-subject variability in the physiology of the gastrointestinal 
tract, gastrointestinal tract transit period and in certain instances to 
region-specific (narrow absorption window) of drug [60]. However, 
modern technical development has resulted into various emerging 
pharmaceutical strategies, especially controlled release systems to 
effectively resolve this issue [61, 62]. Due to tremendous therapeutic 
benefits, orally controlled dosage forms have been developed in the 
previous few years [63-65]. Gastroretentive technology is one 
illustration where characteristics such as prolonged gastric 
retention combined with controlled-release medication dramatically 
increased patient compliance [61, 66-68]. 
Extent of drug absorption from duodenum and jejunum is minimal, 
as transit through this area is fast. This phenomenon drastically 
limits the success of conventional delivery system [69, 70]. The 
failure of conventional approaches in gastric retention has 
contributed to the production of gastroretentive technologies. These 
delivery systems have been engineered to maintain an extended 
interval of time in the upper gastrointestinal tract, after which drugs 
are released into a controlled manner. Prolonged interaction of 
gastroretentive devices with absorption layer permits improved 
bioavailability of medicament [39, 71-73]. Such devices are 
especially useful for drugs predominantly absorbed in the regions of 
the duodenum and upper jejunum [69]. Various technical strategies 
have been explored in order to establish delivery systems that can 
be retained into the stomach. These methods have been suggested 
for improving retention in upper section of the gastrointestinal tract 
[74]. These gastroretentive dosage forms are classified into various 
approaches as shown in fig. 2, such as floating systems [75-
77], expandable systems [78, 79], bioadhesive systems [80-83], high-
density systems [84, 85], superporous hydrogels [78, 
86], magnetic systems [86, 87], dual working systems [88, 89] etc.  
 
 
Fig. 2: Different approaches of gastroretentive drug delivery 
systems 
 
Advantages of gastroretentive strategies 
Gastroretentive technologies are gaining popularity due to 
numerous advantages and patient compliance benefits. Some 
significant benefits of this system are mentioned in the subsequent 
section. Various narrow absorption window drugs may show 
advantageous results after compounding into gastroretentive dosage 
forms. Maximum drug utilization with limited negative 
consequences, low dosing frequency thus improved patient 
compliance besides controlled drug release behavior present the 
benefits of continuous and uniform blood drug level. The medication 
concentration variability is also significantly reduced. In addition, 
side effects based on dosage may also be minimized [90-95]. 
Salient benefits 
Following are some important benefits of gastroretentive delivery 
systems [95-98]. 
• Enhancing bioavailability as well as the therapeutic efficacy 
of molecules with narrow absorption window in the upper 
gastrointestinal tract. 
• Enhanced utilization of medicaments with limited side effects. 
• Low dosing frequency thus improved patient comfort and 
compliance. 
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• Controlled drug release behavior provides uniform and 
consistent blood level of medication. 
• Variations in drug concentration are reduced. Hence, concentration-
dependent side effects may be minimized. 
• Avoiding gastric irritation due to sustained release profile. 
• Site specificity. 
• Uniform release of the drug without risk of dose dumping. 
• Reduced inter-and intra-subject variability. 
• Increased stomach retention period owing to buoyancy 
principle, circumventing the invariable and inadequate absorption of 
drugs. 
• Versatility in the design of dosage form. 
• Extended patent rights along with emerging newer market 
prospect. 
Current viewpoint on gastroretentive approaches 
Various gastroretentive drug delivery systems have been 
investigated for successful gastric retention. However, alteration in 
gastric retention time, especially in fed as well as fasted state, is still 
one of the major challenges for the 
scientists. Therefore, it is advantageous to explore suitable 
innovative gastroretentive approaches by overcoming the 
drawbacks of a particular approach. Various combined approaches 
might be a beneficial strategy for reducing the irregularity of gastric 
retention time. Also, coupled working system is less affected due to 
physiological state of the gut for instance, as in fed and fasting 
conditions. These advanced systems may ensure delayed gastric 
empting. Therefore, a study on gastroretentive drug 
delivery systems in the near future should be with major concern of 
combining various strategies to achieve desired stomach retention 
of dosage forms also in fasted condition [39, 89, 99, 100]. The use of 
newer techniques such as extrusion and amalgamation of various 
approaches will further create interest in gastroretentive drug 
delivery systems and it will continue to create interest among 
pharmaceutical industries and researchers [57]. Various 
gastroretentive floating drug delivery systems investigated for 
Helicobacter pylori eradication are portrayed in fig. 3.  
 
 
Fig. 3: Various floating dosage forms for eradication of H. pylori 
 
Miscellaneous research considerations on eradication of 
Helicobacter pylori through gastroretentive techniques have been 
published. Few of these findings are presented in table 1. 
  
Table 1: Gastroretentive drug delivery approaches for eradication of Helicobacter pylori 
S. No. Drug Dosage form Authors Year Ref. (s) 
1. Levofloxacin hydrochloride Gastroretentive wafers Li et al. 2020 [101] 
2. Amoxicillin trihydrate Floating mucoadhesive alginate beads Dey et al. 2016 [102] 
3. Metronidazole Floating pH-sensitive chitosan hydrogel El Mahrouk et al. 2016 [103] 
4. Amoxicillin and clarithromycin Floating assembled modules Rossi et al. 2016 [104] 
5. Amoxicillin trihydrate Floating mucoadhesive beads Thombre et al. 2016 [105] 
6. Clarithromycin Floating mucoadhesive alginate beads Adebisi et al. 2015 [106] 
7. Clarithromycin Floating fine granules Aoki et al. 2015 [107] 
8. Clarithromycin Floating tablets Ugurlu et al. 2014 [108] 
9. Clarithromycin Floating mucoadhesive beads Gattani et al. 2010 [109] 
10. Metronidazole Floating alginate beads Javadzadeh et al. 2010 [110] 
11. Clarithromycin Gellan gum-based floating beads Rajinikanth et al. 2009 [111] 
12. Amoxicillin Gastroretentive minimatrices Badhan et al. 2009 [112] 
13. Clarithromycin Mucoadhesive microspheres Jain et al. 2009 [113] 
14. Clarithromycin Floating gelling system Rajinikanth et al. 2008 [114] 
15. Acetohydroxamic acid Floating gelling system Rajinikanth et al. 2008 [115] 
16. Metronidazole Floating alginate beads Ishak et al. 2007 [116] 
17. Amoxicillin Intra gastric floating gelling system Rajinikanth et al. 2007 [117] 
18. Acetohydroxamic acid Gellan based floating beads Rajinikanth et al. 2007 [118] 
19. Amoxicillin Mucoadhesive microspheres Patel et al. 2007 [119] 
20. Metronidazole Floating emulsion gel beads Sriamornsak et al. 2005 [120] 
21. Acetohydroxamic acid Floating microspheres Umamaheshwari et al. 2003 [121] 
22. Acetohydroxamic acid Floating mucoadhesive microspheres Umamaheshwari et al. 2002 [122] 
23. Ampicillin Floating sustained release liquid 
preparation 
Katayama et al. 1999 [123] 
24. Tetracycline and metronidazole Floating tablets Yang et al. 1999 [124] 
 
CONCLUSION  
H. pylori is a global pathogen and its infection causes various clinical 
and pathological effects involving chronic gastritis, peptic ulcer, 
malignant stomach tumours etc. Development of an efficient 
gastroretentive dosage form is a real challenge for the eradication of 
bacterium by delivering suitable antibiotic in the stomach. The 
present review provides an insight of different aspects of this spiral 
gram-negative bacterium along with various antibiotic regimens 
available for the treatment of infection prevailing in all classes of 
people around the world. Immense potential of promising 
gastroretentive technologies for eradication of this prevalent 
contagion are highlighted in the current manuscript. Various 
research endeavours in the avenue of gastroretentive drug delivery 
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ensuring maximal absorption of the antibiotic for eradication of the 
bacterium have also been discussed. 
FUTURE PERSPECTIVES 
Advancements are needed on technical and scientific aspects in this 
area for the development of novel and versatile gastroretentive 
dosage forms so as to eradicate the bacterium efficiently and 
successfully. It is also emphasized that sophisticated research based 
on enhanced stability profile and prolonged residence time of 
dosage forms should be investigated to achieve better penetration of 
antibiotics through the stomach mucus layer to act on H. pylori. 
Progress in synergistic approaches utilizing superior drug delivery 
technologies may prove a useful prospect for improved 
pharmacotherapy of this complex infection. In addition, further 
additional in vivo studies are required to establish the suitability of 
gastroretentive formulations for targeting actives to the gastric wall. 
Moreover, studies regarding antibiotics delivery to target receptor 
sites on H. pylori or circumvent the adhesion of bacteria to the 




All the authors have contributed equally. 
CONFLICT OF INTERESTS  
No conflict of interest 
REFERENCES 
1. Proenca Modena JL, Acrani GO, Brocchi M. Helicobacter pylori: 
phenotypes, genotypes and virulence genes. Future Microbiol 
2009;4:223-40.  
2. Fang Y, Fan C, Xie H. Effect of Helicobacter pylori infection on 
the risk of the acute coronary syndrome: a systematic review 
and meta-analysis. Medicine 2019;98:18348-59.  
3. Kang SJ, Kim DH, Lee BJ. NMR study on small proteins from 
Helicobacter pylori for antibiotic target discovery: a review. 
Molecules 2013;18:13410-24.  
4. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol 
Rev 1997;10:720-41.  
5. Bridge DR, Merrell DS. Polymorphism in the Helicobacter pylori 
CagA and VacA toxins and disease. Gut Microbes 2013;4:101-17.  
6. Lee DS, Moss SF. Targeting Helicobacter pylori in gastric 
carcinogenesis. Expert Opin Ther Targets 2007;11:757-69.  
7. Herszenyi L, Bakucz T, Barabás L, Tulassay Z. Pharmacological 
approach to gastric acid suppression: past, present, and future. 
Dig Dis 2020;38:104-11.  
8. Kabir S. The current status of Helicobacter pylori vaccines: a 
review. Helicobacter 2007;12:89-102.  
9. Torres J, Perez GP, Ximenez C, Munoz L, Camorlinga Ponce M, 
Ramos F, et al. The association of intestinal parasitosis and H. 
pylori infection in children and adults from a mexican 
community with a high prevalence of parasitosis. Helicobacter 
2003;8:179-85.  
10. Kumar S, Kumar A, Dixit VK. Evidences showing association of 
interleukin-1B polymorphisms with increased risk of gastric 
cancer in an Indian population. Biochem Biophys Res Commun 
2009;387:456-60.  
11. Lai FP, Tu YF, Sheu BS, Yang YJ. Maternal H. pylori 
seropositivity is associated with gestational hypertension but is 
irrelevant to fetal growth and development in early childhood. 
BMC Pediatr 2019;19:501-10.  
12. Pachathundikandi SK, Tegtmeyer N, Arnold IC, Lind J, Neddermann 
M, Falkeis-Veits C, et al. T4SS-dependent TLR5 activation by 
Helicobacter pylori infection. Nat Commun 2019;10:1-11.  
13. Umamaheshwari RB, Jain NK. Receptor-mediated targeting of 
lipobeads bearing acetohydroxamic acid for eradication of 
Helicobacter pylori. J Controlled Release 2004;99:27-40.  
14. Ben Mansour K, Fendri C, Battikh H, Garnier M, Zribi M, Jlizi A, 
et al. Multiple and mixed Helicobacter pylori infections: 
comparison of two epidemiological situations in tunisia and 
france. Infect Genet Evol 2016;37:43-8.  
15. Bazzoli F, Bianchi Porro G, Bianchi MG, Molteni M, Pazzato P, 
Zagari RM. Treatment of Helicobacter pylori infection. Indications 
and regimens: an update. Dig Liver Dis 2002;34:70-83.  
16. Egemen A, Yilmaz O, Akil I, Altuglu I. Evaluation of association 
between hepatitis a and Helicobacter pylori infections and 
routes of transmission. Turk J Pediatr 2006;48:135-9.  
17. Cardenas VM, Boller F, Roman GC. Helicobacter pylori, vascular 
risk factors and cognition in US older adults. Brain Sci 
2019;9:370-86.  
18. Shinmura T, Adachi K, Yamaguchi Y, Izawa S, Hijikata Y, Ebi M. 
Vonoprazan-based triple-therapy could improve the efficacy of 
the tailored therapy of Helicobacter pylori infection. J 
Gastrointestin Liver Dis 2019;28:389-95.  
19. Annibale B, Capurso G, Delle Fave G. Consequences of 
Helicobacter pylori infection on the absorption of 
micronutrients. Dig Liver Dis 2002;341:72-7.  
20. Vollaard AM, Verspaget HW, Ali S, Visser LG, Veenendaal RA, 
Van Asten HA, et al. Helicobacter pylori infection and typhoid 
fever in Jakarta, Indonesia. Epidemiol Infect 2006;134:163-70.  
21. Shinohara K, Miyazaki K, Noda N, Saitoh D, Terada M, Wakasugi 
H. Gastric diseases related to Helicobacter pylori and epstein 
barr virus infection. Microbiol Immunol 1998;42:415-21.  
22. De Falco M, Lucariello A, Iaquinto S, Esposito V, Guerra G, De 
Luca A. Molecular mechanisms of Helicobacter pylori 
pathogenesis. J Cell Physiol 2015;230:1702-7.  
23. Kim A, Servetas SL, Kang J, Kim J, Jang S, Choi YH, et al. 
Helicobacter pylori outer membrane protein, HomC, shows 
geographic dependent polymorphism that is influenced by the 
Bab family. J Microbiol 2016;54:846-52.  
24. Gong Y, Yuan Y. Resistance mechanisms of Helicobacter pylori 
and its dual target precise therapy. Crit Rev Microbiol 
2018;44:1-22.  
25. Bin Saeed AA. Is there a link between seropositivity to 
Helicobacter pylori and hepatitis A virus? a systematic review. 
Int J Infect Dis 2010;14:567-71.  
26. Gonzalez A, Casado J, Chueca E, Salillas S, Velazquez Campoy A, 
Espinosa Angarica V, et al. Repurposing dihydropyridines for 
treatment of Helicobacter pylori infection. Pharmaceutics 
2019;11:681-99.  
27. Backert S, Neddermann M, Maubach G, Naumann M. 
Pathogenesis of Helicobacter pylori infection. Helicobacter 
2016;21:19-25.  
28. De Bernard M, Josenhans C. Pathogenesis of Helicobacter pylori 
infection. Helicobacter 2014;19:11-8.  
29. Greenfield LK, Jones NL. Modulation of autophagy by 
Helicobacter pylori and its role in gastric carcinogenesis. Trends 
Microbiol 2013;21:602-12.  
30. Burucoa C, Axon A. Epidemiology of Helicobacter pylori 
infection. Helicobacter 2017;22:1-5.  
31. Cid TP, Fernandez MC, Benito Martinez S, Jones NL. Pathogenesis 
of Helicobacter pylori infection. Helicobacter 2013;18:12-7.  
32. Chang WL, Yeh YC, Sheu BS. The impacts of H. pylori virulence 
factors on the development of gastroduodenal diseases. J 
Biomed Sci 2018;25:68-77.  
33. Zhang Y, Zhou X, Zhang Q, Zhang Y, Wang X. Involvement of NF-
κ B signaling pathway in the regulation of PRKAA1-mediated 
tumorigenesis in gastric cancer tumorigenesis in gastric cancer. 
Artif Cells Nanomed Biotechnol 2019;47:3677-86.  
34. Atherton JC, Blaser JM. Coadaptation of Helicobacter pylori and 
humans ancient history, modern implications. J Clin Invest 
2009;119:2475-87.  
35. Queralt N, Araujo R. Analysis of the survival of H. pylori within a 
laboratory-based aquatic model system using molecular and 
classical techniques. Microb Ecol 2007;54:771-7.  
36. Suzuki H, Hibi T, Marshall BJ. Helicobacter pylori: present status 
and future prospects in japan. J Gastroenterol 2007;42:1-15.  
37. Algood HMS, Cover TL. Helicobacter pylori persistence: an 
overview of interactions between H. pylori and host immune 
defenses. Clin Microbiol Rev 2006;19:597-613.  
38. Kusters JG, Van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter 
pylori infection. Clin Microbiol Rev 2006;19:449-90.  
39. Adebisi AO, Conway BR. Modification of drug delivery to 
improve antibiotic targeting to the stomach. Ther Delivery 
2015;6:741-62.  
Pahwa et al. 
Int J App Pharm, Vol 13, Issue 3, 2021, 5-10 
9 
40. Rico MR, Moreno Y, Barat JM. In vitro antimicrobial activity of 
immobilised essential oil components against Helicobacter 
pylori. World J Microbiol Biotechnol 2020;36:1-9.  
41. Kiesslich R, Goetz M, Burg J, Stolte M, Siegel E, Maeurer MJ, et al. 
Diagnosing Helicobacter pylori in vivo by confocal laser 
endoscopy. Gastroenterology 2005;128:2119-23.  
42. Dzierzanowska Fangrat K, Lehours P, Megraud F, 
Dzierzanowska D. Diagnosis of Helicobacter pylori infection. 
Helicobacter 2006;11:6-13.  
43. Pahwa R, Nath A, Sharma PC, Kumar V, Kohli K. Impact of 
Helicobacter pylori on the prevalence of gastroduodenal 
diseases. Drug Invent Today 2010;2:258-63.  
44. De Boer WA, Tytgat GNJ. Treatment of Helicobacter pylori 
infection. Br Med J 2000;320:31-4.  
45. Homan M, Orel R. Are probiotics useful in Helicobacter pylori 
eradication? World J Gastroenterol 2015;21:10644-53.  
46. Charoenying T, Patrojanasophon P, Ngawhirunpat T, Rojanarata T, 
Akkaramongkolporn P, Opanasopit P. Fabrication of floating 
capsule-in-3D-printed devices as gastro-retentive delivery systems 
of amoxicillin. J Drug Delivery Sci Technol 2020;55:101393.  
47. Chey WD, Wong BC. American college of gastroenterology 
guideline on the management of Helicobacter pylori infection. 
Am J Gastroenterol 2007;102:1808-25.  
48. Harris A. Treatment of Helicobacter pylori. World J 
Gastroenterol 2001;7:303-7.  
49. Wolle K, Malfertheiner P. Treatment of Helicobacter pylori. Best 
Pract Res Clin Gastroenterol 2007;21:315-24.  
50. Van der Hulst R W M, Van der Ende A, Homan A, Roorda P, 
Dankert J, Tytgat G. Influence of metronidazole resistance on 
the efficacy of quadruple therapy for Helicobacter pylori 
eradication. Gut 1998;42:166-9.  
51. Chan FK, Sung JJ, Suen R, Wu JC, Ling TK, Chung SC. Salvage 
therapies after failure of Helicobacter pylori eradication with 
ranitidine bismuth citrate-based therapies. Aliment Pharmacol 
Ther 2000;14:91-5.  
52. Conway BR. Drug delivery strategies for the treatment of 
Helicobacter pylori infections. Curr Pharm Des 2005;11:775-90.  
53. Verma A, Dubey J, Hegde RR, Rastogi V, Pandit JK. Helicobacter 
pylori: past, current, future treatment strategies with 
gasrtoretentive drug delivery systems. J Drug Targeting 
2016;24:897-915.  
54. Berthenet E, Sheppard S, Vale FF. Recent "omics" advances in 
Helicobacter pylori. Helicobacter 2016;21:14-8.  
55. Yanaka A, Fahey JW, Fukumoto A, Nakayama M, Inoue S, Zhang 
S, et al. Dietary sulforaphane-rich broccoli sprouts reduce 
colonization and attenuate gastritis in Helicobacter pylori-
infected mice and humans. Cancer Prev Res 2009;2:353-60.  
56. Han YM, Park JM, Lee D, Oh JY, Hahm KB. Korean probiotic 
kimchi prevented Helicobacter pylori-associated gastric cancer 
in mice and human. FASEB J 2017;31:1067-71. 
57. Kumar M, Kaushik D. An overview on various approaches and 
recent patents on gastroretentive drug delivery systems. 
Recent Pat Drug Delivery Formulation 2018;12:84-92.  
58. Adibkia K, Hamedeyazdan S, Javadzadeh Y. Drug release 
kinetics and physicochemical characteristics of floating drug 
delivery systems. Expert Opin Drug Delivery 2011;8:891-903.  
59. Wu Y, Zhang W, Huang J, Luo Z, Li J, Wang L. Mucoadhesive 
improvement of alginate microspheres as potential 
gastroretentive delivery carrier by blending with bletilla striata 
polysaccharide. Int J Biol Macromol 2020;156:1191-201.  
60. Kotreka UK, Adeyeye MC. Gastroretentive floating drug-
delivery systems: a critical review. Crit Rev Ther Drug Carrier 
Syst 2011;28:47-99.  
61. El Nabarawi MA, Teaima MH, El-Monem RAA, El Nabarawy NA, 
Gaber DA. Formulation, release characteristics, and 
bioavailability study of gastroretentive floating matrix tablet 
and floating raft system of mebeverine HCl. Drug Des Dev Ther 
2017;11:1081-93.  
62. Pahwa R, Bisht S, Kumar V, Kohli K. Recent advances in gastric 
floating drug delivery technology: a review. Curr Drug Delivery 
2013;10:286-98.  
63. Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable 
gastroretentive dosage forms. J Controlled Release 
2003;90:143-62.  
64. Mandal UK, Chatterjee B, Senjoti FG. Gastro-retentive drug 
delivery systems and their in vivo success: a recent update. 
Asian J Pharm Sci 2016;11:575-84.  
65. Soni H, Ghulaxe C, Upadhyay S, Pillai S. Development and in 
vitro evaluation of an oral floating tablet of metronidazole. J 
Drug Delivery Ther 2018;8:83-6.  
66. Sheikh FA, Hussain MA, Ashraf MU, Haseeb MT, Farid-ul-Haq M. 
Linseed hydrogel-based floating drug delivery system for 
fluoroquinolone: design, in vitro drug release and in vivo real-
time floating detection. Saudi Pharm J 2020;28:538-49.  
67. Pahwa R, Singh M, Kumar V, Kohli K. Recent advances and 
patent perspectives in gastroretentive technology. Recent Pat 
Drug Delivery Formulation 2012;6:278-90.  
68. Schneider F, Koziolek M, Weitschies W. In vitro and in vivo test 
methods for the evaluation of gastroretentive dosage forms. 
Pharmaceutics 2019;11:416-45.  
69. Awasthi R, Kulkarni GT. Decades of research in drug targeting 
to the upper gastrointestinal tract using gastro retention 
technologies: where do we stand? Drug Delivery 
2016;23:378-94.  
70. Hoffman A, Stepensky D, Lavy E, Eyal S, Klausner E, Friedman 
M. Pharmacokinetic and pharmacodynamic aspects of 
gastroretentive dosage forms. Int J Pharm 2004;277:141-53.  
71. Lopes CM, Bettencourt C, Rossi A, Buttini F, Barata P. Overview 
on gastroretentive drug delivery systems for improving drug 
bioavailability. Int J Pharm 2016;510:144-58.  
72. Sopyan I, Sriwidodo, Wahyuningrum R, Aliza PN. A review: 
floating drug delivery system as a tool to improve dissolution 
rate in gastric. Int J Appl Pharm 2020;12:10-3. 
73. Ghoneim AM, Tadros MI, Alaa-Eldin AA. Spray-dried silica 
xerogel nanoparticles as a promising gastroretentive carrier 
system for the management of chemotherapy-induced nausea 
and vomiting. Int J Nanomed 2019;14:9619-30.  
74. Malik R, Garg T, Goyal AK, Rath G. Polymeric nanofibers: 
targeted gastro-retentive drug delivery systems. J Drug 
Targeting 2015;23:109-24.  
75. Mohapatra PR, Satyavani CH, Sahoo S. Design and development 
of carvedilol gastroretentive floating drug delivery systems 
using hydrophilic polymers and in vitro characterization. Int J 
Pharm Pharm Sci 2020;12:66-73.  
76. Chen R, Guo X, Liu X, Cui H, Wang R, Han J. Formulation and 
statistical optimization of gastric floating alginate/oil/chitosan 
capsules loading procyanidins: in vitro and in vivo evaluations. 
Int J Biol Macromol 2018;108:1082-91.  
77. Vasvari G, Haimhoffer A, Horvath L, Budai I, Trencsenyi G, 
Beresova M. Development and characterization of 
gastroretentive solid dosage form based on melt foaming. AAPS 
PharmSciTech 2019;20:1-11.  
78. Mirani AG, Patankar SP, Kadam VJ. Risk-based approach for 
systematic development of gastroretentive drug delivery 
system. Drug Delivery Transl Res 2016;6:579-96.  
79. Zhao S, Lv Y, Zhang J Bin, Wang B, Lv GJ, Ma XJ. Gastroretentive 
drug delivery systems for the treatment of Helicobacter pylori. 
World J Gastroenterol 2014;20:9321-9.  
80. Pawar VK, Kansal S, Asthana S, Chourasia MK. Industrial 
perspective of gastroretentive drug delivery systems: 
physicochemical, biopharmaceutical, technological and 
regulatory consideration. Expert Opin Drug Delivery 
2012;9:551-65.  
81. Ishak RAH. Buoyancy-generating agents for stomach-specific 
drug delivery: an overview with special emphasis on floating 
behavior. J Pharm Pharm Sci 2015;18:77-100.  
82. Raviteja G, Narayana RKVV, Baskaran M, Meghana G, Ganesh G. 
A mucoadhesive gastroretentive dosage form for valacyclovir. 
Int J Pharm Pharm Sci 2014;6:422-7.  
83. Simons FJ, Wagner KG. Modeling, design and manufacture of 
innovative floating gastroretentive drug delivery systems 
based on hot-melt extruded tubes. Eur J Pharm Biopharm 
2019;137:196-208.  
84. Du F, Wu Y, Du F, Zhang L, Feng W, Zhao L. Construction of 
catechol-grafted chitosan alginate/barium sulfate 
microcapsules for computed tomography real-time imaging 
and gastroretentive drug delivery. Int J Nanomed 
2019;14:6001-18.  
Pahwa et al. 
Int J App Pharm, Vol 13, Issue 3, 2021, 5-10 
10 
85. Prajapati ST, Patel LD, Patel CN. Polymers for floating drug 
delivery system. Syst Rev Pharm 2011;2:1-7.  
86. Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. 
Gastroretentive dosage forms: overview and special case of 
Helicobacter pylori. J Controlled Release 2006;111:1-18.  
87. Melocchi A, Uboldi M, Inverardi N, Briatico Vangosa F, Baldi F, 
Pandini S. Expandable drug delivery system for gastric 
retention based on shape memory polymers: development via 
4D printing and extrusion. Int J Pharm 2019;571:118700.  
88. Singh BN, Kim KH. Floating drug delivery systems: an approach 
to oral controlled drug delivery via gastric retention. J 
Controlled Release 2000;63:235-59.  
89. Tripathi J, Thapa P, Maharjan R, Jeong SH. Current state and 
future perspectives on gastroretentive drug delivery systems. 
Pharmaceutics 2019;11:1-22.  
90. Adebisi A, Conway BR. Gastroretentive microparticles for drug 
delivery applications. J Microencapsulation 2011;28:689-708.  
91. Streubel A, Siepmann J, Bodmeier R. Drug delivery to the upper 
small intestine window using gastroretentive technologies. 
Curr Opin Pharmacol 2006;6:501-8.  
92. Nayak AK, Maji R, Das B. Gastroretentive drug delivery 
systems: a review. Asian J Pharm Clin Res 2010;3:2-10.  
93. Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D, Kulkarni GT. 
Gastroretentive dosage forms: a review with special emphasis 
on floating drug delivery systems. Drug Delivery 2011;18:97-
110.  
94. Murphy C, Pillay V, Choonara Y, Du Toit L. Gastroretentive drug 
delivery systems: current developments in novel system design 
and evaluation. Curr Drug Delivery 2009;6:451-60.  
95. Prajapati VD, Jani GK, Khutliwala TA, Zala BS. Raft forming 
system-an upcoming approach of gastroretentive drug delivery 
system. J Controlled Release 2013;168:151-65.  
96. Pahwa R, Saini N, Kumar V, Kohli K. Chitosan-based 
gastroretentive floating drug delivery technology: an updated 
review. Expert Opin Drug Delivery 2012;9:525-39.  
97. Talukder R, Fassihi R. Gastroretentive delivery systems: a mini 
review. Drug Dev Ind Pharm 2004;30:1019-28.  
98. Sathish D, Himabindu S, Shravan Kumar Y, Shayeda, 
Madhusudan Rao Y. Floating drug delivery systems for 
prolonging gastric residence time: a review. Curr Drug Delivery 
2011;8:494-510.  
99. Bera H, Maiti S, Saha S, Nayak AK. Biopolymers-based 
gastroretentive buoyant systems for therapeutic management 
of Helicobacter pylori infection. Polysaccharide Carriers Drug 
Delivery 2019;713-36. DOI:10.1016/B978-0-08-102553-
6.00024-6 
100. Pahwa R, Jindal S, Chhabra L, Dutt H, Rao R. Development and 
in vitro characterization of effervescent floating drug delivery 
system of famotidine. Int J Pharm Sci Res 2012;3:241-6. 
101. Li Z, Zeng R, Yang L, Ren X, Maffucci KG, Qu Y. Development and 
characterization of PCL electrospun membrane-coated Bletilla 
striata polysaccharide-based gastroretentive drug delivery 
system. AAPS PharmSciTech 2020;21:1-14. 
102. Dey SK, De PK, De A, Ojha S, De R, Mukhopadhyay AK, et al. 
Floating muco adhesive alginate beads of amoxicillin 
trihydrate: a facile approach for H. pylori eradication. Int J Biol 
Macromol 2016;89:622-31. 
103. El Mahrouk GM, Abouleinien MH, Makhlouf AI. Design, 
optimization and evaluation of novel metronidazole loaded 
gastroretentive pH sensitive hydrogel. AAPS PharmSciTech 
2016;17:1285-97.  
104. Rossi A, Conti C, Colombo G, Castrati L, Scarpignato C, Barata P, 
et al. Floating modular drug delivery systems with buoyancy 
independent of release mechanisms to sustain amoxicillin and 
clarithromycin intra-gastric concentrations. Drug Dev Ind 
Pharm 2016;42:332-9.  
105. Thombre NA, Gide PS. Floating-bioadhesive gastroretentive 
Caesalpinia pulcherrima-based beads of amoxicillin trihydrate 
for Helicobacter pylori eradication. Drug Delivery 2016;23:405-
19. 
106. Adebisi AO, Laity PR, Conway BR. Formulation and evaluation 
of floating mucoadhesive alginate beads for targeting 
Helicobacter pylori. J Pharm Pharmacol 2015;67:511-24. 
107. Aoki H, Iwao Y, Mizoguchi M, Noguchi S, Itai S. Clarithromycin 
highly-loaded gastro floating fine granules prepared by high-
shear melt granulation can enhance the efficacy of Helicobacter 
pylori eradication. Eur J Pharm Biopharm 2015;92:22-7. 
108. Ugurlu T, Karacicek U, Rayaman E. Optimization and evaluation 
of clarithromycin floating tablets using experimental mixture 
design. Acta Pol Pharm 2014;71:311-21. 
109. Gattani SG, Savaliya PJ, Belgamwar VS. Floating mucoadhesive 
beads of clarithromycin for the treatment of Helicobacter pylori 
infection. Chem Pharm Bull 2010;58:782-7. 
110. Javadzadeh Y, Hamedeyazdan S, Adibkia K, Kiafar F, Zarrintan 
MH, Barzegar-Jalali M. Evaluation of drug release kinetics and 
physico-chemical characteristics of metronidazole floating 
beads based on calcium silicate and gas-forming agents. Pharm 
Dev Technol 2010;15:329-38. 
111. Rajinikanth PS, Mishra B. Stomach site specific drug delivery 
system of clarithromycin for eradication of Helicobacter pylori. 
Chem Pharm Bull 2009;57:1068-75. 
112. Badhan AC, Mashru RC, Shah PP, Thakkar AR, Dobaria NB. 
Development and evaluation of sustained release 
gastroretentive minimatrices for effective treatment of H. pylori 
infection. AAPS PharmSciTech 2009;10:459-67. 
113. Jain SK, Jangdey MS. Lectin conjugated gastroretentive 
multiparticulate delivery system of clarithromycin for the 
effective treatment of Helicobacter pylori. Mol Pharmaceutics 
2009;6:295-304. 
114. Rajinikanth PS, Mishra B. Floating in situ gelling system for 
stomach site-specific delivery of clarithromycin to eradicate H. 
pylori. J Controlled Release 2008;125:33-41. 
115. Rajinikanth PS, Mishra B. Floating in situ gelling system of 
acetohydroxamic acid for clearance of H. pylori. Drug Dev Ind 
Pharm 2008;34:577-87. 
116. Ishak RA, Awad GA, Mortada ND, Nour SA. Preparation, in vitro 
and in vivo evaluation of stomach-specific metronidazole-
loaded alginate beads as local anti-Helicobacter pylori therapy. J 
Controlled Release 2007;119:207-14. 
117. Rajinikanth PS, Balasubramaniam J, Mishra B. Development 
and evaluation of a novel floating in situ gelling system of 
amoxicillin for eradication of Helicobacter pylori. Int J Pharm 
2007;335:114-22.  
118. Rajinikanth PS, Mishra B. Preparation and in vitro 
characterization of gellan based floating beads of 
acetohydroxamic acid for eradication of H. pylori. Acta Pharm 
2007;57:413-27. 
119. Patel JK, Patel MM. Stomach specific anti-Helicobacter pylori 
therapy: preparation and evaluation of amoxicillin-loaded 
chitosan mucoadhesive microspheres. Curr Drug Delivery 
2007;4:41-50. 
120. Sriamornsak P, Thirawong N, Puttipipatkhachorn S. Emulsion 
gel beads of calcium pectinate capable of floating on the gastric 
fluid: effect of some additives, hardening agent or coating on 
release behavior of metronidazole. Eur J Pharm Sci 
2005;24:363-73. 
121. Umamaheshwari RB, Jain S, Bhadra D, Jain NK. Floating 
microspheres bearing acetohydroxamic acid for the treatment 
of Helicobacter pylori. J Pharm Pharmacol 2003;55:1607-13. 
122. Umamaheswari RB, Jain S, Tripathi PK, Agrawal GP, Jain NK. 
Floating-bioadhesive microspheres containing 
acetohydroxamic acid for clearance of Helicobacter pylori. Drug 
Delivery 2002;9:223-31. 
123. Katayama H, Nishimura T, Ochi S, Tsuruta Y, Yamazaki Y, 
Shibata K, et al. Sustained release liquid preparation using 
sodium alginate for eradication of Helicobacter pylori. Biol 
Pharm Bull 1999;22:55-60. 
124. Yang L, Eshraghi J, Fassihi R. A new intragastric delivery system 
for the treatment of Helicobacter pylori associated gastric ulcer: 
in vitro evaluation. J Controlled Release 1999;57:215-22. 
 
